Arena Pharmaceuticals (ARNA) slides 7.8% and adds to a 6.5% loss on Friday after the EU's CHMP health regulator didn't make a decision about approving the company's Belviq weight-loss treatment at meetings last week, meaning the firm will have to wait for at least another month for a ruling. It doesn't help that Arena received a 180-day list of questions about Belviq. "It's not pretty," says Adam Feuerstein. (Arena 8-K)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Jan 14, 2015)
at Benzinga.com (Jan 13, 2015)
at Nasdaq.com (Jan 8, 2015)
at CNBC.com (Jan 7, 2015)
at Benzinga.com (Jan 7, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs